Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | AKR1C4 | P17516 | 3/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 3/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 3/20 | 0.42 |
| ▸ | AKR1C1 | Q04828 | 3/20 | 0.42 |
| ▸ | HSPD1 | P10809 | 2/20 | 0.42 |
| ▸ | HSPE1 | P61604 | 2/20 | 0.42 |
| ▸ | BCL2L1 | Q07817 | 2/20 | 0.42 |
| ▸ | PSD | A5PKW4 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NSD2 | O96028 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11332675 | 0.85 | AKR1C4 (0.50) | MAOAMAOBERN1AKR1C4AKR1C3 | |
| SCHEMBL11522993 | 0.82 | ERN1 (0.50) | ERN1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL4122753 | 0.82 | AKR1C3 (0.64) | ERN1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL31652668 | 0.82 | AKR1C3 (0.64) | ERN1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| Hydrochloric Acid SCHEMBL11522996 | 0.80 | AKR1C3 (0.62) | ERN1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL3203329 | 0.79 | ABL1 (0.45) | ERN1HSPD1HSPE1BCL2L1MEN1 | |
| SCHEMBL12316474 | 0.79 | KDM4E (0.46) | MAOAMAOBAKR1C4AKR1C3AKR1C2 | |
| SCHEMBL659333 | 0.79 | AKR1C4 (0.67) | ERN1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL29613154 | 0.79 | AKR1C4 (0.67) | ERN1AKR1C4AKR1C3AKR1C2AKR1C1 | |
| SCHEMBL2070725 | 0.79 | AKR1C4 (0.67) | MAOBERN1AKR1C4AKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 62 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114751870-B | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxybenzoate and derivative thereof, and synthetic method and application thereof | 贵州医科大学 | 2023-10-20 | — | — | CN | claimed |
| CN-114751870-A | 2- (isoxazole-5-yl) phenyl-3, 4-dihydroxy benzoate and derivative thereof, and synthesis method and application thereof | 贵州医科大学 | 2022-07-15 | — | — | CN | claimed |
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | BIODERM RESEARCH (US) | 2008-10-16 | — | — | US | claimed |
| US-20060269494-A1 | New Ubiquitin-Proteasome Regulating Compounds and Their Application in Cosmetic and Pharmaceutical Formulations | GUPTA SHYAM K | 2006-11-30 | — | — | US | claimed |
| US-20060110415-A1 | Topical Delivery System for Cosmetic and Pharmaceutical Agents | BIODERM RESEARCH (US) | 2006-05-25 | — | — | US | claimed |
| US-20060074108-A1 | Matrix metalloprotease (MMP) inhibitors and their application in cosmetic and pharmaceutical composition | BIODERM RESEARCH (US) | 2006-04-06 | — | — | US | claimed |
| US-20050271608-A1 | Skin whitening compositions based on hydroxyaryl alkyl ketones and their isosteric derivatives | GUPTA SHYAM K | 2005-12-08 | — | — | US | claimed |
| US-12558341-B2 | Oral complement factor D inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2026-02-24 | — | — | US | disclosed |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2025-06-12 | — | — | US | disclosed |
| WO-2025076441-A1 | COMPOUNDS OF GCN2 MODULATORS | Alesta Therapeutics BV (NL) | 2025-04-10 | — | — | WO | disclosed |
| EP-3498693-B1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2024-10-30 | — | — | EP | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | VIVIDION THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| WO-2009100250-A1 | CHROMENE DERIVATIVES AND USE THEREOF AS HIF HYDROXYLASE ACTIVITY INHIBITORS | FIBROGEN, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| WO-2009062990-A2 | EQUILIBRATIVE NUCLEOSIDE TRANSPORTER ENT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2009-05-22 | — | — | WO | disclosed |
| US-20090130154-A1 | Topical Delivery of Biological and Cosmetic Agents by Zeolites | BIODERM RESEARCH (US) | 2009-05-21 | — | — | US | disclosed |
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | BIODERM RESEARCH (US) | 2008-10-16 | — | — | US | disclosed |
| US-20080139507-A1 | Method of Treating Skin Condition Including Acne, Skin Aging, Body Odor & Diaper Rash by Zinc Zeolite Clathrates | BIODERM RESEARCH (US) | 2008-06-12 | — | — | US | disclosed |
| US-20070072833-A1 | Survivin inhibitors | ABBVIE INC. | 2007-03-29 | — | — | US | disclosed |
| US-20060269494-A1 | New Ubiquitin-Proteasome Regulating Compounds and Their Application in Cosmetic and Pharmaceutical Formulations | GUPTA SHYAM K | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072833-A1 | Survivin inhibitors | XIAP, BIRC5, BIRC3 | MAOA 3595/4885MAOB 2516/4885ERN1 3476/4885 |
| US-20090130154-A1 | Topical Delivery of Biological and Cosmetic Agents by Zeolites | TYR, MMP1, MMP17 | MAOA 309/4885MAOB 346/4885ERN1 3744/4885 |
| US-12558341-B2 | Oral complement factor D inhibitors | CFD, CFH, CFB | MAOA 1416/4885MAOB 1035/4885ERN1 3303/4885 |
| US-20080254130-A1 | Skin Antiaging & Brightening via Multi-function Treatment of Enzyme Dysfunction | PSMB1, PLOD3, CUTA | MAOA 109/4885MAOB 340/4885ERN1 2391/4885 |
| US-20240226114-A1 | INHIBITORS AND USES THEREOF | KEAP1, NQO1, NFE2L2 | MAOA 2550/4885MAOB 2144/4885ERN1 677/4885 |
| US-20250186391-A1 | ORAL COMPLEMENT FACTOR D INHIBITORS | CFD, CFH, CFB | MAOA 795/4885MAOB 453/4885ERN1 1832/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.